Dr Alan Palmer joins One Nucleus

pharmafile | September 27, 2010 | Appointment | Research and Development One Nucleus, apppointment, research and development 

Cambridge, UK-based life sciences body One Nucleus has appointed Dr Alan Palmer as a director.

Alan is co-founder and chief scientific officer for speciality pharma company MS Therapeutics and has 30 years’ experience in the biotechnology sector in roles spanning academia, research and industry.

Commenting on his appointment he said: “These are challenging times and One Nucleus is extremely well placed to support the biotechnology sector. I am delighted to have been asked to join the board and look forward to bringing my experience to the table, to support the team and One Nucleus members into the future.”

Advertisement

Alan began his medical research career as a principal investigator at both the Alzheimer’s disease Research Centre and the Head Injury Research Centre at the University of Pittsburgh.

This was followed by a stint at Wyeth Research, before co-founding Cerebrus (which later became Vernalis), Pharmidex Pharmaceutical Services and then followed by MS Therapeutics.

Harriet Fear, chief executive of One Nucleus, said: “Alan is a great addition to the team. He has a deep understanding of the needs of One Nucleus members, and this coupled with his academic and pharma background makes him an ideal director for One Nucleus.”

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content